ArticleFrontiers in oncology2025
Prognosis of nodal micrometastasis in resectable pN0 non-small cell lung cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nodal micrometastasis (NMM) is the presence of a small cluster of tumor cells in a regional lymph node. However, the prognostic value of NMM in resectable NSCLC is still debated. Methods: This retrospective cohort study at Maharaj Nakorn Chiang Mai Hospital from 2006 to 2017 assesses the prognostic impact of nodal micrometastasis in resectable pN0 NSCLC patients, using immunohistochemistry staining for cytokeratin AE1/AE3, p53, and BerEp4. Patients are categorized into three groups: pN0 without nodal micrometastasis, pN0 with nodal micrometastasis, and pN+. Overall survival is the primary endpoint, with disease-free survival as the secondary endpoint. Results: Out of 225 patients, 98 had pathological N0 (pN0) status and 127 had pathological N positive (pN+) status. Among pN0 patients, nodal micrometastasis was found in 21 cases (21.43%), distributed as follows: 2 (2.04%) in hilar and interlobar regions (N1), 17 (17.35%) in the mediastinal region (N2), and 2 in both hilar and mediastinal regions (N1+N2) (2.04%).Univariable analysis revealed that male sex and the presence of tumor necrosis increased both the recurrence rate of lung cancer and the mortality rate, whereas larger tumor size, intra-tumoral vascular invasion, and pleural invasion were associated solely with cancer recurrence. However, multivariable analysis showed no statistically significant difference in disease-free survival and overall survival between pN0 patients with and without NMM, with hazard ratios of 0.98 (95% CI: 0.31-3.08, P=0.973) and 1.11 (95% CI: 0.23-5.42, P=0.900), respectively. Conclusion: Nodal micrometastasis was identified in 21.43% of pN0 resectable NSCLC patients. However, the benefits of NMM detection in resectable cases remain controversial due to conflicting results from retrospective studies. Larger prospective cohort studies are needed to better understand disease prognosis and inform treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.